Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
Titel:
Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
Auteur:
Barlesi, F. Scherpereel, A. Gorbunova, V. Gervais, R. Vikström, A. Chouaid, C. Chella, A. Kim, J.H. Ahn, M.J. Reck, M. Pazzola, A. Kim, H.T. Aerts, J.G Morando, C. Loundou, A. Groen, H.J.M. Rittmeyer, A.